HARMONY 6 – Albiglutide Non-inferior on Efficacy to Humalog on top of Lantus, but competition better positioned to tap this market

April 2012 | 4 pages | ID: H65DDE581D2EN
MP Advisors

Abstracts

GSK reported that topline data from Harmony 6 study met the primary end point. Albiglutide produced clinically significant reductions in HbA1c vs. preprandial lispro insulin (Humalog, LLY) on top of Lantus after 26 wks of treatment. We do not see meaningful potential for albiglutide in the insulin population as the competition (IdegLira and Lyxumia-Lantus fixed dose combination) are better poised. Because of superior post prandial glucose lowering impact of Lyxumia, the Lyxumia-Lantus fixed doses combination (will enter PhIII in 2013) should offer the best benefit in this population, while IdegLira would score on lower hypoglycemia and weight loss benefit.

Contents

COMPANIES MENTIONED

GlaxoSmithKline, Novo Nordisk, Amylin